Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 2/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.56 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058586 | 1.00 | CHKA (0.68) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10573768 | 0.85 | CHKA (0.62) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL2219585 | 0.83 | CHKA (0.83) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL11136934 | 0.81 | CHKA (1.00) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL15475876 | 0.81 | CHKA (0.58) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL10062533 | 0.80 | CHKA (0.77) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL10403382 | 0.80 | CHKA (0.60) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL6388962 | 0.80 | CHKA (0.57) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL7498608 | 0.79 | CHKA (0.75) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10403769 | 0.79 | CHKA (0.59) | CHKANR4A2SOS2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3521283-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| EP-3517534-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | disclosed |
| US-20230114091-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230108114-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2022-04-28 | — | — | US | disclosed |
| WO-2021126729-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2018-11-29 | — | — | US | disclosed |
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2017-08-10 | — | — | US | disclosed |
| US-9637475-B2 | Compounds for treating cancer | ABIVAX (FR) | 2017-05-02 | — | — | US | disclosed |
| WO-2016193503-A2 | ANALOGUES OF HYDROXYCHLOROQUINE (HCQ) WITHOUT RETINAL TOXICITY | INOVIEM SCIENTIFIC (FR) | 2016-12-08 | — | — | WO | disclosed |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-22 | — | — | US | disclosed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | disclosed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226095-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | CHKA 3601/4885NR4A2 72/4885SOS2 4346/4885 |
| US-20230114091-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CHKA 2378/4885NR4A2 3706/4885SOS2 4262/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | CHKA 927/4885NR4A2 1321/4885SOS2 1857/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | CHKA 2695/4885NR4A2 22/4885SOS2 2820/4885 |
| US-20150299129-A1 | COMPOUNDS FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | CHKA 3301/4885NR4A2 34/4885SOS2 3992/4885 |
| US-20220127253-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | CHKA 3601/4885NR4A2 72/4885SOS2 4346/4885 |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | CHKA 3601/4885NR4A2 72/4885SOS2 4346/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CHKA 2378/4885NR4A2 3706/4885SOS2 4262/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | CHKA 3136/4885NR4A2 41/4885SOS2 3669/4885 |
| US-20230108114-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CHKA 2228/4885NR4A2 3559/4885SOS2 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.